TY  - JOUR 
AU  - Antela López, Antonio
PY  - 2014
SN  - 1473-3099
UR  - http://hdl.handle.net/20.500.11940/5888
LA  - eng
TI  - Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
DO  - 10.1016/S1473-3099(14)70796-0
T2  - LANCET INFECTIOUS DISEASES
M2  - 590
VL  - 14
ER  -